RVVTF.US Revive Therapeutics Ltd

Healthcare Pharmaceuticals USA Stocks
0.0112 USD
Close of Nov 17, 2026
0.0060 0.0585
Market cap
USD 4.98M
P/E
-
P/B
0.78x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is RVVTF.US undervalued?

Graham number

The Graham number of Revive Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Revive Therapeutics Ltd fundamental analysis

No fundamental analysis for Revive Therapeutics Ltd yet.

Revive Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Revive Therapeutics Ltd

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. The company develops Bucillamine-based therapies, psilocybin-based therapeutics, and Long COVID diagnostics, as well as commercializes delivery technologies for psychedelics and cannabinoids. Revive Therapeutics Ltd. was founded in 2012 and is based in Toronto, Canada.

Full company profile